39262-14-1 人参皂苷 CK

WGK Germany:WGK 3 存储类别:11 - 可燃固体 危险性类别:急性毒性 类别4 经口

• 简介 人参皂苷CK是原人参二醇型皂苷在人肠道内的主要代谢产物。研究表明,人参皂苷的药理活性主要是通过其代谢组分CK介导的,并且CK具有多种药理活性,如抗炎、抗肿瘤、抗过敏、抗糖尿病、保肝、神经保护、心血管保护等。
• 据报道人参皂苷C-K具有抗皱作用。此外，它还增强了HCT116结肠癌中肿瘤坏死因子(TNF)相关的凋亡诱导配体(TRAIL)诱导的凋亡。
• 生物活性 Ginsenoside C-K 是一种 Ginsenoside Rb1 的细菌代谢物。Ginsenoside C-K 通过抑制诱生型一氧化氮合酶 (iNOS) 和 COX-2 来发挥抗炎作用。在人肝微粒体中，Ginsenoside C-K 抑制 CYP2C9 和 CYP2A6 活性，IC50 分别为 32.0±3.6 μM和 63.6±4.2 μM。
• 靶点 COX-2 iNOS CYP2C9 32 μM (IC 50 ) CYP2A6 63.6 μM (IC 50 )
• 体外研究 Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects mainly by reducing inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)-2, and proinflammatory cytokines. Ginsenoside C-K suppresses the expression of proinflammatory cytokines by downregulating the activities of IRAK-1, MAPKs, IKK-α, and NF-κB in LPS-treated murine peritoneal macrophages. Ginsenoside C-K also suppresses the expression of iNOS and COX-2 by inhibiting NF-κB signaling in LPS-stimulated RAW264.7 cells. In zymosan-treated bone-marrow-derived macrophages (BMDMs) and RAW264.7 cells, Ginsenoside C-K inhibits inflammatory responses by negatively regulating the secretion of proinflammatory cytokines, the activation of MAPKs, and the generation of ROS. In addition, anti-inflammatory activity of Ginsenoside C-K has been observed in LPS-stimulated microglial cells. Ginsenoside C-K hinders inflammatory responses by controlling both the generation of ROS and the activities of MAPKs, NF-κB, and AP-1. Ginsenoside C-K, a major metabolite of ginsenosides in the gastrointestinal tract, inhibits NF-κB signaling in a PXR-dependent manner. Ginsenoside C-K is shown to promote recovery of dextran sulfate sodium (DSS) -induced colitis by suppressing NF-κB activation. Ginsenoside C-K significantly reduces TNF-α-induced upregulation of IL-1β and iNOS mRNA levels, and restores the mRNA levels of PXR and CYP3A4 in LS174T cells. Ginsenoside C-K, one of the intestinal metabolites of 20(S)-protopanaxadiol derivatives, exhibits an inhibition against the activity of CYP2C9 in human liver microsomes with an IC 50 value of 32.0±3.6 μM, a weak inhibition against the activity of CYP2A6 in human liver microsomes with an IC 50 value of 63.6±4.2 μM, and an even weaker inhibition against the activity of CYP2D6 in human liver microsomes with an IC 50 value of more than 100 μM.